Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
Alexandra Yakusheva, Preclinical Scientist at EFS, shared a post on LinkedIn:
“Excited to share something I’ve been working on over the past months.
Together with an amazing team, we have founded ThrombInnov, a CRO dedicated to thrombosis and haemostasis research, with the goal of making advanced preclinical models more accessible to academia and industry.
I’m proud to be one of the co-founders of this project and excited to contribute to building it from the ground up.
Today is also the first day of ISTH 2026, where Pierre Mangin and I will be representing ThrombInnov.
If you’re attending the congress and would like to discuss preclinical thrombosis models, collaborations or simply say hello, we’d be delighted to meet you.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC